Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06378086 · ClinicalTrials.gov registry record · NA
RHA® Redensity With New Anesthetic Agent Perioral Rhytids (PAS)
A NA study of Pain and Aging, sponsored by Teoxane.
- Active
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT06378086: Active NA study of Pain and Aging, sponsored by Teoxane.
NCT06378086 is a NA study of Pain and Aging that is active but no longer recruiting, run by Teoxane. The registered enrollment target is 20 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06378086, a NA study of Pain and Aging, is active but no longer recruiting, sponsored by Teoxane.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a randomized, controlled, double-blinded, within-subject (split-face), multicenter, prospective study to investigate whether RHA® Redensity with new anesthetic agent is non-inferior to RHA® Redensity with lidocaine in terms of injection site pain felt by the subject during injection. At screening, the Principal Investigator (PI) evaluated subjects' perioral rhytid severity (using the Perioral Rhytid Severity Rating Scale; PR-SRS) to confirm eligibility and to establish a pre-treatment score for assessing aesthetic improvement. At Visit 1, RHA® Redensity with new anesthetic agent was administered in a random sequence (first or second injection) and side of the mouth (left or right) and RHA® Redensity with lidocaine was administered to the other side. Study subjects and the PI injecting study devices were blinded. Immediately after injection of an upper perioral quadrant, subjects rated the injection site pain experienced during injection using a 100 mm Visual Analog Scale (VAS). Injection site pain in each side of the mouth was also assessed at 15, 30, 45 and 60 minutes after injection of the upper quadrant. Safety evaluation consisted of AE assessments, a 30-day CTR (Common Treatment Response) diary and a follow-up call performed by the study site at 72 hours after injection. Subjects attended Visit 2 (30 days post-injection) where effectiveness and safety assessments were conducted. Subjects who presented with an unresolved clinically significant device related AE at Visit 2 received a optional follow-up phone call no later than 30 days after Visit 2. If the clinically significant AE remained unresolved, the Investigator requested that the subject attended the optional in-clinic follow-up visit (i.e., Visit 3) within 5 working days. Follow-up of the clinically significant AE continued until the AE was resolved or the TI determines that additional follow-up was not necessary.
Primary Outcome
Injection pain during injection was measured on the 100 mm Visual Analog Scale (VAS), as assessed by subjects immediately after injection of each upper perioral quadrant. VAS is a 100 mm Visual Analog Scale with 0 meaning no pain and 100 meaning intolerable pain
Interventions
- DEVICE RHA® Redensity with new anesthetic agent
- DEVICE RHA® Redensity with lidocaine
Study Locations (3)
Alabama
- United States - Birmingham
New York
- United States, New York - New York
Other
- Puerto Rico - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-06-11 |
| Est. Completion | 2025-09 |
| Phase | NA |
What the registry record for NCT06378086 still lists
NCT06378086 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which RHA® Redensity with new anesthetic agent is the first listed.
NCT06378086 reports a single indexed study location in Alabama, New York, Other.
Frequently Asked Questions
What is clinical trial NCT06378086 about?
NCT06378086 is a clinical study titled "RHA® Redensity With New Anesthetic Agent Perioral Rhytids (PAS)". This is a randomized, controlled, double-blinded, within-subject (split-face), multicenter, prospective study to investigate whether RHA® Redensity with new anesthetic agent is non-inferior to RHA® Redensity with lidocaine in terms of injection site pain felt by the subject during injection. At scr...
What is the current status of trial NCT06378086?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-06-11. Estimated completion is 2025-09.
What conditions does trial NCT06378086 study?
This clinical trial studies the following conditions: Pain, Aging.
What interventions are being tested in trial NCT06378086?
The interventions under investigation include: RHA® Redensity with new anesthetic agent (DEVICE), RHA® Redensity with lidocaine (DEVICE).
Who is sponsoring clinical trial NCT06378086?
This trial is sponsored by Teoxane, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06378086 being conducted?
This trial has 3 study locations across Alabama, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06378086's enrollment target sits among peer trials
20 338th of 374 higher than 29 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Postoperative Pain After Activation of Irrigant
RECRUITING · NA
-
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)
RECRUITING · NA
-
Pain With Dementia
RECRUITING · NA
-
Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI